Dupixent – BiotechReality – Information Intelligence System for Biopharma

Sanofi announces that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare and serious autoimmune skin disorder. This is the first and only targeted therapy to be available for this patient population in the United States. Bullous pemphigoid is a chronic autoimmune condition marked by the appearance of large blisters filled with fluid on the skin. The disease can be severely itchy and painful and, in extreme cases, can result in widespread blistering, skin erosions, and extreme disability. It is estimated to occur in about 27,000 adults in the U.S., many of whom have their disease not controlled well with systemic corticosteroids. Also Read: Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden. The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone. Patrick Dunn The FDA approval of Dupixent for the treatment of BP is informed by results from the Phase 2/3 ADEPT trial. In the ADEPT trial, Dupixent showed a substantial increase in sustained remission of disease and decreased itch and oral corticosteroid use over placebo in adult patients with moderate-to-severe BP. Some of the ADEPT study findings at 36 weeks Sustained Disease Remission: 18.3% of Dupixent-treated patients sustained disease remission, compared with 6.1% of the placebo group Reduction in Itch: Clinically meaningful itch reduction was seen in 38.3% of Dupixent-treated patients, versus 10.5% of the placebo group. Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with the debilitating impact of blisters and lesions, and potentially co-morbid conditions. By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve sustained remission and reduce itch. This approval in the US is important for the thousands of patients living with bullous pemphigoid, and we look forward to working with regulators around the world to bring this innovative medicine to more patients in need. Alyssa Johnsen, MD, PhD Dupixent is a human monoclonal antibody and is administered as a subcutaneous injection. It does not act as an immunosuppressant. Dupixent inhibits the IL-4 and IL-13 pathways' signaling it is are thought to be the driving forces of the inflammation in bullous pemphigoid. The most frequent adverse events that occurred in patients treated with Dupixent in the study were arthralgia (joint pain), conjunctivitis, blurred vision, herpes viral infections, and keratitis.Dupixent has also been approved for numerous other uses, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, and has won regulatory approval in more than 60 countries. The medication is jointly being developed by Sanofi and Regeneron to a global collaboration agreement. Source: Sanofi Last Modified:

Tag: Dupixent

FDA Approves Sanofi’s Dupixent (dupilumab) as First and Only Targeted Medicine for Bullous Pemphigoid in the U.S.

Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment